(Press-News.org) A mechanism involving potassium channels in the brain that control brain cell activity could provide a new and fundamentally different way of treating depression symptoms in adults with major depressive disorder, according to two complementary papers published recently by researchers at the Icahn School of Medicine at Mount Sinai.
In two new research articles, published in Biological Psychiatry and Molecular Psychiatry, the researchers provide new insights into how a drug called ezogabine may impact the brain to improve depression.
“Depression is a devastating public health problem, and our understanding of what changes in the brain to cause the illness is still very limited,” says James Murrough, MD, PhD, Director of the Depression and Anxiety Center for Discovery and Treatment at Mount Sinai and senior author of both studies. “Our work represents a major step in unraveling the potential role of a specific protein complex in the brain—the KCNQ channel—and how targeting it could eventually offer a significant new modality for treating depression.”
Ezogabine was approved by the U.S. Food and Drug Administration in 2011 as an anticonvulsant medication for partial-onset seizures in adults with epilepsy. Previous neuroscience research in mice, conducted by researchers at The Friedman Brain Institute at Mount Sinai, suggested that increasing KCNQ channel activity could also represent a new approach to treating depression.
Building on these findings, Dr. Murrough’s research team became the first to test the hypothesis in humans with depression. That study, published in the American Journal of Psychiatry in 2021, revealed ezogabine was associated with significant improvements in depression symptoms and the ability to experience pleasure (anhedonia) in patients who were treated with the drug compared to patients who received placebo. The two new papers provide details from new analyses of the human brain imaging data collected from that initial clinical trial.
The first of the two papers, published in Molecular Psychiatry, sheds light on the effects of ezogabine on a specific brain pathway. This study examined the impact of ezogabine on the ventral tegmental area (VTA) of the brain, which is involved in the release of dopamine, a neurotransmitter essential for motivation, pleasure, and reinforcement of behaviors. The results, based on functional magnetic resonance imaging, showed an important role for KCNQ channel openers like ezogabine in normalizing hyperactivity of the VTA in people with both depression and anhedonia.
“Up to half of people with depression do not respond to first-line treatment, which may be due to the lack of interventions that directly affect the neurobiology underlying symptoms like anhedonia,” says Laurel S. Morris, PhD, Adjunct Professor of Psychiatry at the Icahn School of Medicine and first author of the paper. “By specifically targeting VTA activity and connectivity, ezogabine could open the door to decidedly improved outcomes for people who struggle daily with depression and anhedonia.”
In a second paper, published in Biological Psychiatry, research revealed that ezogabine was able to normalize connectivity between the brain’s key reward regions and larger-scale brain networks including the posterior cingulate cortex, which plays a key role in internally directed thought and negative emotions. Patients who experienced greater improvement in their depression and anhedonia when treated with ezogabine showed decreased connectivity between brain reward regions and the cingulate cortex.
Together, these two complementary studies suggest that KCNQ channel openers can potentially alleviate the specific known neurobiological changes that occur in animal models of depression as well as change the function of larger brain networks that might be uniquely used in humans to regulate thought processes such as rumination.
“These findings suggested to us that drugs targeting the KCNQ channel may trigger antidepressant effects by reducing interactions between the reward centers in the brain and those related to negative thinking and emotion,” Dr. Murrough explains. “This hypothesis will require confirmation in larger clinical trials.”
Dr. Murrough is a named inventor on a pending patent application for the use of ezogabine and other KCNQ channel openers to treat depression and related disorders.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.
###
END
Autism spectrum disorder (ASD) is a condition affecting the brain’s development and often affects the ability of a person to perceive sensory information and social cues and socialize with others. Recent studies have revealed that environmental factors and epigenetic processes, such as DNA methylation, are crucial to the development of ASD. Notably, immune activation and exposure to stress hormones are known to alter neuronal activity in the dorsal raphe (DR, a region of the brain involved in serotonin signaling), contributing ...
Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among which is the meta-analysis of data from the PROTECTED TAVR and BHF PROTECT TAVI Trials
Background
The embolisation of debris after transaortic valve implantation (TAVI) for the treatment of aortic stenosis can lead to stroke. Cerebral embolic protection (CEP) devices, which can capture this debris and thus lower the incidence of stroke, have been deployed during ...
Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the FAITAVI randomised clinical trial (RCT).
Background
The optimal management of patients with intermediate coronary artery disease (CAD) and severe aortic stenosis (AS) who are candidates for TAVI remains unclear. Recent trials comparing percutaneous coronary intervention ...
Background
While dual antiplatelet therapy (DAPT) has long been the standard of care for the management of acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), there is an increasing awareness of the need to find a more patient-centred approach that strikes a balance between the ischaemic protection DAPT offers and the risk of bleeding complications it can create.
The effect of DAPT in dosage and duration on cardiovascular events and bleeding after implantation of drug-coated stents (DCS) in ACS patients, ...
Research Highlights:
The American Heart Association’s PREVENTTM risk calculator accurately identified participants who had calcium buildup in their heart arteries and those who had a higher future heart attack risk, in an analysis of about 7,000 adults in New York City referred for heart disease screening.
The PREVENT scores also predicted future heart attack risk.
Embargoed until 4 a.m. CT/5 a.m. ET Wednesday, May 21, 2025
DALLAS, May 21, 2025 — The PREVENTTM risk calculator helped to identify people with plaque buildup in the arteries of the heart, in addition to predicting their risk of a future heart attack, according ...
Researchers at the Johns Hopkins Applied Physics Laboratory (APL) in Laurel, Maryland, have developed a new, easily manufacturable solid-state thermoelectric refrigeration technology with nano-engineered materials that is twice as efficient as devices made with commercially available bulk thermoelectric materials. As global demand grows for more energy-efficient, reliable and compact cooling solutions, this advancement offers a scalable alternative to traditional compressor-based refrigeration.
In a paper published in ...
Researchers at the Francis Crick Institute have shown that gonadotrophs, cells in the pituitary gland with a key role in puberty and reproduction, come from two different populations, with the majority produced after birth rather than in the embryo, as previously thought.
A better understanding of when these important cells develop could help researchers and clinicians understand and treat disorders that impact puberty and fertility.
In the pituitary, a small gland located in the middle of the head and connected to the brain, gonadotrophs ...
By carefully placing nanostructures on a flat surface, researchers at Linköping University, Sweden, have significantly improved the performance of so-called optical metasurfaces in conductive plastics. This is a major step for controllable flat optics, with future applications such as video holograms, invisibility materials, and sensors, as well as in biomedical imaging. The study has been published in the journal Nature Communications.
To control light, curved lenses are used today, that are often made of glass that is either concave or convex, ...
Halving the number of times vital signs and neurological function are checked in low-risk patients after treatment for acute ischaemic stroke does not compromise care or recovery, according to new findings presented at the 11th European Stroke Organisation Conference in Helsinki, Finland.
Results from the Optimal Post rTpa-Iv Monitoring in Ischaemic Stroke Trial (OPTIMISTmain)1, simultaneously published in The Lancet, also showed that this approach also had flow-on benefits for nursing workflow and intensive care resources. The trial was led by Professor Craig Anderson from The George Institute for Global Health and UNSW ...
External walls of buildings are normally lifeless and have no additional function. An international team of researchers and companies, in which Carole Planchette from the Institute of Fluid Mechanics and Heat Transfer is involved, wants to change this by adding microbial life to building façades. In the project “Archibiome tattoo for resistant, responsive, and resilient cities” (REMEDY), the consortium is working on integrating specifically composed communities of beneficial microorganisms into ...
